AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This program initially aims to recruit 1300 breast cancer patients from a large number of hospitals across Europe. Eligible patients are those who are 18 or older, either female or male, and who have not received more than 1 type of treatment from the time metastases were discovered, metastasi(e)s has just been diagnosed or their disease has come back (disease relapse). Biopsy samples from both the primary and metastatic (or relapsed) tumor will be collected for central analyses, together with blood, serum and plasma samples. Any samples not analyzed immediately will be stored in an independent bio-repository to enable future (not yet defined) research aimed at better understanding metastatic breast cancer. In summary, the main objectives of AURORA are to better understand the genetic aberrations in metastatic breast cancer and to discover the mechanisms of response or resistance to therapy, in order to ultimately identify the "right therapy for each individual patient". At the same time, patients with genetic aberrations that are being targeted by new drugs in development will be offered the possibility to participate in clinical trials, when approved and available in their countries. Ultimately, the aim of AURORA is to improve the outcomes of all patients diagnosed with metastatic breast cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta lub mężczyzna w wieku co najmniej 18 lat z zaawansowanym rakiem piersi lub rakiem przerzutowym, który nie był wcześniej leczony więcej niż jednym schematem terapeutycznym
- •Pisemna zgoda na uczestnictwo w badaniu
- •Stan ogólny według skali ECOG 0 lub 1 (pacjent zdolny do codziennych aktywności)
- •Dostępność tkanki pierwotnego guza do badań naukowych
- •Dostępność przerzutu do pobrania próbki tkanki i zgoda pacjenta na biopsję
- •Pobranie próbki przerzutu przed rozpoczęciem lub podczas leczenia pierwszej linii
- •Dostępność próbek krwi, surowicy i osocza pobranej podczas badania początkowego
- •Zgoda na regularne pobieranie próbek krwi w trakcie badania i obserwacji
✗ Disqualifies
- •Pacjent otrzymał więcej niż jeden schemat leczenia systemowego w przypadku raka przerzutowego
- •Pacjent otrzymał radioterapię paliatywną do jedynego dostępnego miejsca do biopsji
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 16, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (52)
Institut Jules Bordet
Brussels, Belgium
Cliniques Universitaires St-Luc
Brussels, Belgium
Grand Hopital Charleroi
Charleroi, Belgium
UZ Leuven
Leuven, Belgium
CHU de Liège
Liège, Belgium
Clinique et Maternité Sainte-Elisabeth (CMSE - Namur)
Namur, Belgium
Kliniken Essen-Mitte, Klinik für Senologie/ Brustzentrum
Essen, Germany
Frauenkliniken Maistrasse-Innenstadt und Großhadern
München, Germany
Landspitali
Reykjavik, Iceland
Ospedale degli Infermi - S.O.C.Oncologia
Biella, Italy
Ospedale di Bolzano - Oncologia Medica
Bolzano, Italy
Ospedale Ramazzini di Carpi
Carpi, Italy
IRCCS AOU San Martino-IST
Genova, Italy
ULSS 21 Legnago
Legnago, Italy
Istituto Europeo di Oncologia
Milan, Italy
UOC Oncologia Medica - AOU Parma
Parma, Italy
Fondazione Salvatore Maugeri
Pavia, Italy
IRCCS Az Ospedaliera S.Maria Nuova
Reggio Emilia, Italy
Centre Hospitalier
Luxembourg, Luxembourg
Champalimaud Foundation
Lisbon, Portugal
Complexo Hospitalario Universitario A Coruña
A Coruña, Spain
Hospital del Mar
Barcelona, Spain
Dr Rosell Oncology Institute, Quirón Dexeus University Hospital
Barcelona, Spain
Hospital Vall d'Hebron
Barcelona, Spain
Consorcio Hospitalario Provincial de Castellón
Castellon, Spain
Hospital San Pedro de Alcantara
Cáceres, Spain
Hospital Universitari Arnau de Vilanova
Lleida, Spain
MD Anderson Cancer Center
Madrid, Spain
Hospital Clínico San Carlos
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Centro Integral Oncológico Clara Campa
Madrid, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Instituto Valenciano de Oncología
Valencia, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
Hospital General Universitario de Valencia
Valencia, Spain
Sahlgrenska University Hospital
Gothenburg, Sweden
Ryhov County Hospital
Jönköping, Sweden
Kantonsspital Baden
Baden, Switzerland
Inselspital Bern
Bern, Switzerland
Kantonsspital Graubuenden
Chur, Switzerland
Luzerner Kantonsspital, Division of Medical Oncology
Lucerne, Switzerland
Queen Elizabeth Hospital - University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
University Hospitals Bristol NHS Foundation Trust
Bristol, United Kingdom
Velindre NHS Trust
Cardiff, United Kingdom
NHS Tayside, Ninewells Hospital
Dundee, United Kingdom
Edinburgh Cancer Centre - Western General Hospital
Edinburgh, United Kingdom
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
Christie NHS Foundation Trust
Manchester, United Kingdom
Nottingham University Hospital NHS Trust
Nottingham, United Kingdom
Singleton Hospital - ABM University Health Board
Swansea, United Kingdom
Royal Cornwall Hospital - Royal Cornwall Hospitals NHS Trust
Truro, United Kingdom
Yeovil District Hospital NHS Foundation Trust
Yeovil, United Kingdom
Trial contact
AURORA BIG HQ
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.